Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Eric J. Fues and Kyle W. Howarth of Finnegan address the on-sale bar in patent law, with a focus on how pre-filing sales of ...

Between 2005 and 2015, nearly three-fourths of issued drug patents were for already existing drugs. A common argument in ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

The future of American drug innovation is threatened by US regulations that permit knockoff versions of new drugs to be sold ...

With the issuance of this patent, Maxona Pharmaceuticals now holds a total ... After completion of an extensive formulation optimization process and comprehensive IND-enabling pre-clinical studies ...

SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals ... The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including: Process for preparation of RECCE ...

The projected patent number is 12,239,614 and the issue ... SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...